Rehmann Capital Advisory Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Rehmann Capital Advisory Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-12	Closed	-$320	–	1690
2019 Q2	$320	Sell	12 -68	-85%	-$1.74K	﹤0.01%	2011
2019 Q1	$2.15K	Sell	80 -405	-84%	-$9.46K	﹤0.01%	1746
2018 Q4	$7.84K	Buy	485 +417	+613%	+$8.1K	﹤0.01%	1129
2018 Q3	$1.41K	Sell	68 -238	-78%	-$3.75K	﹤0.01%	1899
2018 Q2	$4.67K	Sell	306 -323	-51%	-$5.76K	﹤0.01%	1559
2018 Q1	$14K	Buy	+629	New	+$17.4K	﹤0.01%	1186

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Rehmann Capital Advisory Group's ACAD Position: Q3 2019 in Review

Rehmann Capital Advisory Group sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 12 shares — an estimated $320 sold.

Rehmann Capital Advisory Group first reported a position in ACAD in Q1 2018 and held it in 6 quarters. The position peaked at $14K in Q1 2018. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Rehmann Capital Advisory Group reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Rehmann Capital Advisory Group sold 12 Acadia Pharmaceuticals shares in Q3 2019, an estimated $320.
Rehmann Capital Advisory Group first reported a position in Acadia Pharmaceuticals in Q1 2018 and held it in 6 quarters.
Rehmann Capital Advisory Group's Acadia Pharmaceuticals position peaked at $14K in Q1 2018.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.